sar425899 glucagon glp-1 dual agonist sanofi Clinical relevance of dual agonist of glucagon and glucagon Frontiers | Striking the Balance:

Ease your GLP-1 journey with Side Effect Relief

With the participation of researchers from the Paul Langerhans Institute Dresden (PLID), partner at the German Center for Diabetes Research, a GLP-1 receptor agonist in the form of tablets could for the first time be compared with the most common second-line therapy of T2D, a DPP-IV inhibitor

It is a monosaccharide, which means it is a single sugar molecule

### Funding Statement SDL and AC were supported by the National Science Foundation (Grant Nos.\ CAREER DMS-1944574 and DMS-2325258) ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained

It can sound weak and idealistic but make no mistake: all 3 ingredients in our natural GLP-1 product have been rigorously studied in human clinical trials